

MDRF International Medical Device Regulators Forum

WHO Update

Irena Prat World Health Organization Beijing, 18-20 September 2018



INDRF International Medical Device Regulators Forum

Prequalification of IVDs

- In 2018*, 17 PQ applications:
 - 10 HIV: 5 RDT, 1 EIA, 2 NAT, 2 CD4
 - 3 HCV: 1 RDT, 1 EIA, 1NAT
 - 1 HIV/syphilis: RDT
 - 1 malaria: RDT
 - 1 cholera: RDT
 - 1 G6PD: RDT
- ...and 43* Change Notifications



Prequalification of IVDs

- Implementation of ToC format:
 - Pilot of dossier report template* 2018
 - Dossier format requirement 2019:
 - PQDx18 'Instructions for compilation of a product dossier'
 - Technical specifications series
- PQ scope expanded to syphilis (only) RDTs and HPV IVDs beyond PoC
- 11 laboratories listed as evaluating sites for PQ purposes



INDRF International Medical Device Regulators Forum

Prequalification of IVDs

- Review of IMDRF documents:
 - Principles of Labeling for Medical Devices and IVD Medical Devices
 - Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices



WHO Guidance For Manufacturers I

- Technical specification series (TSS)
 - http://www.who.int/diagnostics_laboratory/guidance/technical_specification_ser ies/en/
 - TSS 1: HIV RDT for professional and/or self-testing
 - TSS 2: IVDs to identify **G6PD** activity
 - TSS 3: Malaria RDT
 - TSS 4: IVD used for the detection of high-risk HPV types in cervical cancer screening
 - TSS 5: RDT used for surveillance and detection of an outbreak of Cholera
 - In development (lay out according to the IMDRF IVD MA table of content)
 - TSS 6: Syphilis RDT (Consultancy meeting 2018 Q3)
 - TSS 7: HCV RDTs (Consultancy meeting 2018 Q4)
 - TSS 8: HIV Enzyme Immunoassays
 - TSS 9: HCV Enzyme Immunoassays (Consultancy meeting 2018 Q4)
 - TSS 10: NAT to detect **HCV** (quantitative) (Consultancy meeting 2019 Q1)
 - TSS 11: NAT to detect **HIV-1** (quantitative) (Consultancy meeting 2019 Q1) 5
 - TSS 12: NAT to detect HIV-1 & HIV-2 (qualitative) (Consultancy meeting 2019 Q1)



WHO Guidance For Manufacturers II

- Technical guidance series (TGS)
 - http://www.who.int/diagnostics_laboratory/guidance/technical_guidance_serie s/en/
 - TGS 1 Standards applicable to the WHO prequalification of IVD
 - TGS 2: Establishing **stability** of an IVD for WHO prequalification (TGS2 Annex: component stability)
 - TGS 3: Principles of **performance studies** of an IVD for WHO prequalification
 - TGS 4: Guidance on test method validation for an IVD
 - TGS 5: Designing 'instructions for use' for IVD
 - TGS 6: Panels for QA and QC of IVD
 - TGS 7: Risk management for manufacturers of IVD (draft)
 - In development
 - TGS 8: Use of **biological reference materials** in the development of IVDs
 - TGS 9: Precision and robustness
 - TGS 10: Accessories



WHO post-market guidance roll-out




Workshops for testing providers & regulators

- Anglophone Africa
- Russophone
- Francophone Africa
- Ukraine



ПОСТРЕГИСТРАЦИОННЫЙ НАДЗОР ЗА МЕДИЦИНСКИМИ ИЗДЕЛИЯМИ ДЛЯ ДИАГНОСТИКИ IN VITRO **Type of IVD complaints received** by WHO (n=107) Defective reagent

Erroneous results



- False negative and false positive
 False positive
- Falsification
- Invalid rate
- Mislabelled
- Software
- Underquantification



International Medical Device Regulators Forum

PMS: Relevant IMDRF working groups

- Adverse event reporting terminology
 - Must be relevant for low resource-settings, where different IVD types are used to IMDRF regulators
- Unique device identification
 - Must be relevant for post-market surveillance activities
- Labelling
 - Must be relevant for instances when labelling is revised following post-market investigation - FSCA



INDRF International Medical Device Regulators Forum

Thank you